PARNAXLABPharmaceuticals
Parnax Lab Ltd — Profit & Loss Statement
₹128.55
-2.85%
Parnax Lab Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | -0.08 Cr | -0.01 Cr | — |
| Tax Rate For Calcs | 0.26 | 0.20 | 0.30 | 0.33 | — |
| Normalized EBITDA | 28.44 Cr | 24.36 Cr | 23.99 Cr | 23.34 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 11.52 Cr | 9.61 Cr | 8.62 Cr | 8.24 Cr | — |
| Reconciled Depreciation | 7.38 Cr | 6.96 Cr | 6.53 Cr | 5.87 Cr | — |
| Reconciled Cost Of Revenue | 96.00 Cr | 102.81 Cr | 116.34 Cr | 115.02 Cr | — |
| EBITDA | 28.44 Cr | 24.36 Cr | 23.71 Cr | 23.30 Cr | — |
| EBIT | 21.06 Cr | 17.40 Cr | 17.18 Cr | 17.43 Cr | — |
| Net Interest Income | -5.39 Cr | -5.35 Cr | -4.72 Cr | -5.07 Cr | — |
| Interest Expense | 5.39 Cr | 5.35 Cr | 4.90 Cr | 5.17 Cr | — |
| Normalized Income | 11.52 Cr | 9.61 Cr | 8.82 Cr | 8.27 Cr | — |
| Net Income From Continuing And Discontinued Operation | 11.52 Cr | 9.61 Cr | 8.62 Cr | 8.24 Cr | — |
| Total Expenses | 168.35 Cr | 172.13 Cr | 150.86 Cr | 145.82 Cr | — |
| Diluted NI Availto Com Stockholders | 11.52 Cr | 9.61 Cr | 8.62 Cr | 8.24 Cr | — |
| Net Income Common Stockholders | 11.52 Cr | 9.61 Cr | 8.62 Cr | 8.24 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 11.52 Cr | 9.61 Cr | 8.62 Cr | 8.24 Cr | — |
| Minority Interests | -0.02 Cr | -0.02 Cr | -0.01 Cr | -0.02 Cr | — |
| Net Income Including Noncontrolling Interests | 11.54 Cr | 9.62 Cr | 8.63 Cr | 8.26 Cr | — |
| Net Income Continuous Operations | 11.54 Cr | 9.62 Cr | 8.63 Cr | 8.26 Cr | — |
| Tax Provision | 4.13 Cr | 2.42 Cr | 3.65 Cr | 4.01 Cr | — |
| Pretax Income | 15.67 Cr | 12.05 Cr | 12.28 Cr | 12.26 Cr | — |
| Other Non Operating Income Expenses | 1.68 Cr | 0.82 Cr | 0.15 Cr | 0.08 Cr | — |
| Net Non Operating Interest Income Expense | -5.39 Cr | -5.35 Cr | -4.72 Cr | -5.07 Cr | — |
| Interest Expense Non Operating | 5.39 Cr | 5.35 Cr | 4.90 Cr | 5.17 Cr | — |
| Operating Income | 19.39 Cr | 16.58 Cr | 16.75 Cr | 17.21 Cr | — |
| Operating Expense | 72.35 Cr | 69.32 Cr | 34.52 Cr | 30.80 Cr | — |
| Other Operating Expenses | 40.54 Cr | 38.63 Cr | 67000.00 | 0.12 Cr | — |
| Depreciation And Amortization In Income Statement | 7.38 Cr | 6.96 Cr | 6.53 Cr | 5.87 Cr | — |
| Depreciation Income Statement | 7.38 Cr | 6.96 Cr | 6.47 Cr | 5.80 Cr | — |
| Gross Profit | 91.74 Cr | 85.90 Cr | 51.27 Cr | 48.02 Cr | — |
| Cost Of Revenue | 96.00 Cr | 102.81 Cr | 116.34 Cr | 115.02 Cr | — |
| Total Revenue | 187.74 Cr | 188.71 Cr | 167.61 Cr | 163.03 Cr | — |
| Operating Revenue | 187.74 Cr | 188.71 Cr | 167.61 Cr | 163.03 Cr | — |
| Total Unusual Items | — | 0.00 | -0.28 Cr | -0.05 Cr | -0.07 Cr |
| Total Unusual Items Excluding Goodwill | — | 0.00 | -0.28 Cr | -0.05 Cr | -0.07 Cr |
| Interest Income | — | 0.42 Cr | 0.23 Cr | 0.16 Cr | 0.09 Cr |
| Rent Expense Supplemental | — | 0.49 Cr | 0.77 Cr | 0.73 Cr | 0.80 Cr |
| Diluted Average Shares | — | 1.15 Cr | 1.11 Cr | 0.85 Cr | 0.85 Cr |
| Basic Average Shares | — | 1.15 Cr | 1.11 Cr | 0.85 Cr | 0.85 Cr |
| Diluted EPS | — | 8.38 | 7.79 | 9.68 | -0.43 |
| Basic EPS | — | 8.38 | 7.79 | 9.68 | -0.43 |
| Special Income Charges | — | 0.00 | -0.28 Cr | -0.05 Cr | -0.07 Cr |
| Other Special Charges | — | -0.07 Cr | -0.01 Cr | -31000.00 | -0.01 Cr |
| Write Off | — | -34000.00 | 0.29 Cr | 0.05 Cr | 0.08 Cr |
| Total Other Finance Cost | — | 0.08 Cr | 0.05 Cr | 0.06 Cr | 0.10 Cr |
| Interest Income Non Operating | — | 0.42 Cr | 0.23 Cr | 0.16 Cr | 0.09 Cr |
| Amortization | — | 0.11 Cr | 0.06 Cr | 0.07 Cr | 0.06 Cr |
| Research And Development | — | 0.58 Cr | 0.21 Cr | 0.28 Cr | 0.04 Cr |
| Selling General And Administration | — | 7.09 Cr | 6.96 Cr | 6.38 Cr | 4.82 Cr |
| Selling And Marketing Expense | — | 2.27 Cr | 2.40 Cr | 2.22 Cr | 1.18 Cr |
| General And Administrative Expense | — | 4.83 Cr | 4.56 Cr | 4.16 Cr | 3.63 Cr |
| Rent And Landing Fees | — | 0.49 Cr | 0.77 Cr | 0.73 Cr | 0.80 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Parnax Lab Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.